Trial reportBMC musculoskeletal disorders2026
Efficacy and safety of a combination of platelet-rich plasma with non-crosslinked hyaluronic acid versus a crosslinked hyaluronic acid, in single-injection for knee osteoarthritis. Randomized, controlled, multicenter, non-inferiority trial.
Trial report in BMC musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03328728 (A Prospective, Multicenter, Randomized,Controlled Study to Compare the Safety and Performance of Cellular Matrix Device), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Multicenter, Randomized,Controlled Study to Compare the Safety and Performance of Cellular Matrix Device (Combination of Autologous Platelet-rich Plasma and Non-crosslinked Hyaluronic Acid) to Those of Synvisc-One (Crosslinked Hyaluronic Acid) for the Treatment of Mild to Moderate Knee Osteoarthritis
Who cites it
1 citing paper in PubMed.
- Evaluating the Efficacy of Adipose-Derived Stromal Vascular Fraction Injection for Early-Stage Knee Osteoarthritis: A Multicenter Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe potential synergistic effects of the combination of Platelet Rich Plasma with hyaluronic acid remain insufficiently evaluated in randomized controlled trials in symptomatic knee osteoarthritis.
methodsA single-blind intention-to-treat randomized controlled non-inferiority trial was conducted to compared efficacy and safety of a combination of autologous platelet-rich plasma with non-crosslinked hyaluronic acid (PRP-HA) prepared with Cellular Matrix technology (Cellular Matrix A-CP-HA Kit) versus Synvisc-One, a crosslinked hyaluronic acid (HA), in single-injection for moderate knee osteoarthritis with follow-up at 1, 3 and 6 months (WOMAC, SF36). Secondary outcome was to evaluate the percentage of responders at 6 months (OMERACT-OARSI, PASS and WOMAC pain MCII). A 6-month open-label extension phase with a single injection of PRP-HA was offered to patients still symptomatic at 6 months from both groups.
results156 patients were included. Regarding the non-inferiority test, a significant difference between the two groups was demonstrated for the WOMAC pain score on walking at M6, in favor of PRP-HA (-6.34 [-12.51; -0.18], p = 0.04). The percentage of responders in favor of PRP-HA at 6 months was higher for PASS WOMAC Pain (50.6% vs. 33.3%, p = 0.04), whereas no significant differences were found for the OMERACT–OARSI (58% vs. 48%, p = 0.26) and MCII (44.4% vs. 36.0%, p = 0.29) criteria. In the extension phase with PRP-HA, a significant improvement in WOMAC was observed at 12 months, compared with baseline values in both groups.
conclusionsThe combination of PRP with non-crosslinked HA in mono-injection was found to be non-inferior to crosslinked HA, with regards to the percentage of responders over 6 months (WOMAC pain). It also demonstrated a good safety profile in symptomatic knee osteoarthritis.
trial registrationThe clinical trial “Cellular Matrix Device for the Treatment of Mild to Moderate Knee Osteoarthritis” was registered under the trial registration number NCT03328728 on 24 October 2017. The registration was performed retrospectively, as the first patient was enrolled earlier, on 18 July 2017 the primary endpoint and analysis plan were prespecified and unchanged.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.